A NOVEL APPROACH TO INTRALESIONAL AUTOLOGOUS SERUM THERAPY IN MELASMA: AN OPEN-LABEL, PROSPECTIVE STUDY

RAKESH KUMAR MEENA; VIVEK SAGAR; SUDHANSHU SHARMA; DHRUVENDRA PANDEY

doi:10.22159/ajpcr.2023v16i9.49173

Authors

RAKESH KUMAR MEENA Department of Dermatology, Venereology, and Leprosy, Government Autonomous Medical College, Ratlam; Madhya Pradesh, India. https://orcid.org/0009-0000-0662-6168
VIVEK SAGAR Department of Dermatology, Venereology, and Leprosy, Dr. Baba Saheb Ambedkar Medical College and Hospital, Rohini, New Delhi, India https://orcid.org/0009-0005-3121-0160
SUDHANSHU SHARMA Department of Dermatology, Venereology, and Leprosy, Government Autonomous Medical College, Ratlam; Madhya Pradesh, India
DHRUVENDRA PANDEY Department of Community Medicine, Government Autonomous Medical College, Ratlam; Madhya Pradesh, India. https://orcid.org/0000-0002-6791-9447

DOI:

https://doi.org/10.22159/ajpcr.2023v16i9.49173

Keywords:

Melasma, Autologous Serum Therapy, Intralesional, modified Melasma Area and Severity Index

Abstract

Objective: The study aimed to assess the effectiveness of intralesional autologous serum therapy in Melasma.

Methods: A total of 30 patients over 18 years of age were enrolled in the study with prior approval from the institute’s ethical committee. Serum was injected intradermally into the melasma lesions of the patient every 2 weeks with a 30G insulin syringe. Patients were called for follow-up every 15 days until 90 days. On each visit, clinical response to treatment was calculated using the modified Melasma Area and Severity Index (mMASI) score, and side effects were also noted, if any.

Results: The reduction in mean mMASI score from baseline was not significant till the second visit (day 15) (p=0.317), while it was statistically significant from the third visit onwards (day 30) (p=0.024). The reduction in mean mMASI score from baseline 3.95±3.23 to 2.31±2.16 (41.51% improvement) is suggestive of a good response, which was also statistically significant (p≤0.001).

Conclusion: Study patients perceived a significant improvement in pigmentation during the therapy period without any considerable side effects. Thus, autologous serum therapy may be a viable alternative to the existing treatment modalities for Melasma.

Downloads

Download data is not yet available.

References

Sarkar R, Puri P, Jain RK, Singh A, Desai A. Melasma in men: A clinical, etiological and histological study. J Eur Acad Dermatol Venereol 2010; 24:768-72.

Picardo R, Vallejos Q, Feldman SR, Schultz MR, Verma A, Quandt SA, et al. The prevalence of melasma and its association with quality of life among male migrant latino workers. Int J Dermatol 2009; 48:22-6.

Pawaskar MD, Parikh P, Markowski T, Mc Michael AJ, Feldman SR, Balkrishan R. Melasma and its impact on health related QOL in Hispanic women. J Dermatolog Treat 2007; 18:5-9.

Ravaut P: Essai sur L’Autohematotherapie dans quelques dermatoses (article in French). Ann Dermatol Syphiligr . 1913, 4:292–6.

Spiethoff B: Therapeutischen Verwendung des Eigenserums (article in German). Münchener Medizinische Wochenschrift. 1913, 60:521.

Pittler MH, Armstrong NC, Cox A, Collier PM, Hart A, Ernst E. Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. Br J Dermatol. 2003;148:307-13. [PubMed] [Google Scholar]

Behl PN. Practice of Dermatology. 7th ed. New Delhi: Oxford Blackwell Scientific publications; 1990. Autohaemotherapy; p. 76. [Google Scholar]

Anitua E, Pino A, Orive G. Opening new horizons in regenerative dermatology using platelet-based autologous therapies. Int J Dermatol. 2017;56 (3):247–251. doi:10.1111/ijd.13510

Choi SY, Lee YJ, Kim JM, Kang HJ, Cho SH, Chang SE. Epidermal growth factor relieves inflammatory signals in staphylococcus aureus-treated human epidermal keratinocytes and atopic dermatitis-like skin lesions in Nc/Nga mice. Biomed Res Int. 2018;2018(7):1–9.

Kumaravel S, Manjula J, Balamurugan L, Sindhuja S, Anandan H. Chronic autoimmune urticaria and efficacy of autologous serum therapy. Int J Sci Study. 2017;4(11):163–166.

Ghani R. Platelet rich plasma use in the treatment of eczema (atopic dermatitis): case report. Glob Sci J. 2018;6(12):22–31.

Higuchi A. Autologous serum and serum components. Invest Ophthalmol Vis Sci. 2018;59:DES121– DES129. https://doi.org/10.1167/ iovs.17-23760.

Bajaj AK, Saraswat A, Upadhyay A, Damisetty R, Dhar S. Autologous serum therapy in chronic urticaria: Old wine in a new bottle. Indian J Dermatol Venereol Leprol. 2008; 74:109–13. [PubMed] [Google Scholar].

Datta A, Chandra S, Saha A, Sil A, Das NK. Exploring the safety and effectiveness of subcutaneous autologous serum therapy versus conventional intramuscular autologous serum therapy in chronic urticaria: An observer-blind, randomized, controlled study. Indian J Dermatol Venereol Leprol 2020;86:632-42.

García-Millan et al. An Autologous Topical Serum Derived from Platelet-Rich Plasma Therapy for the Management of Sensitive Skin Alterations: A Case Series Report. Clinical, Cosmetic and Investigational Dermatology 2022:15 2077–86.

Panda AK, Jena AK, Panda M, Raj C, Debata I. Micro needling vs micro needling combined with autologous topical platelet rich plasma in the treatment of melasma: a prospective randomized comparative study. Int J Res Dermatol 2022;8:78-84.